Recognition and suppression of transfected plasmids by protein ZNF511-PRAP1, a potential molecular barrier to transgene expression

Molecular Therapy

Volumn 19, Issue 8, 2011, Pages 1478-1486

  Qiu, Guo Hua ^a   Leung, Carol Ho Wing ^a   Yun, Tong ^a   Xie, Xiaojin ^a   Laban, Mirtha ^a   Hooi, Shing Chuan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE 2; HYBRID PROTEIN; PLASMID DNA; PROTEIN P21; RED FLUORESCENT PROTEIN; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; ZNF511 PROLINE RICH ACIDIC PROTEIN 1 FUSION PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN HEP3B; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOMEGALOVIRUS; DEACETYLATION; DNA INTEGRATION; DNA METHYLATION; DNA PROTEIN COMPLEX; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; TRANSCRIPTION REGULATION; TRANSGENE; TRANSIENT TRANSFECTION;

CYTOMEGALOVIRUS;

EID: 79961024414     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.80     Document Type: Article

References (43)

1. Pack, DW, Hoffman, AS, Pun, S and Stayton, PS (2005). Design and development of polymers for gene delivery. Nat Rev Drug Discov 4: 581-593. (Pubitemid 40975711)
2. Zuhorn, IS, Engberts, JB and Hoekstra, D (2007). Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 36: 349-362. (Pubitemid 46626209)
3. Mintzer, MA and Simanek, EE (2009). Nonviral vectors for gene delivery. Chem Rev 109: 259-302.
4. Kim, SS, Garg, H, Joshi, A and Manjunath, N (2009). Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med 15: 491-500.
5. Seow, Y and Wood, MJ (2009). Biological gene delivery vehicles: beyond viral vectors. Mol Ther 17: 767-777.
6. Wiethoff, CM and Middaugh, CR (2003). Barriers to nonviral gene delivery. J Pharm Sci 92: 203-217. (Pubitemid 36169293)
7. Al-Dosari, MS and Gao, X (2009). Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 11: 671-681.
8. Read, ML, Logan, A and Seymour, LW (2005). Barriers to gene delivery using synthetic vectors. Adv Genet 53: 19-46. (Pubitemid 43580681)
9. Zabner, J, Fasbender, AJ, Moninger, T, Poellinger, KA and Welsh, MJ (1995). Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270: 18997-19007.
10. Wu, TL and Ertl, HC (2009). Immune barriers to successful gene therapy. Trends Mol Med 15: 32-39.
11. Bessis, N, GarciaCozar, FJ and Boissier, MC (2004). Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11 Suppl 1: S10-S17. (Pubitemid 39359442)
12. Sakurai, H, Kawabata, K, Sakurai, F, Nakagawa, S and Mizuguchi, H (2008). Innate immune response induced by gene delivery vectors. Int J Pharm 354: 9-15. (Pubitemid 351400322)
13. Haas, T, Metzger, J, Schmitz, F, Heit, A, Müller, T, Latz, E et al. (2008). The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 28: 315-323. (Pubitemid 351335308)
14. Kumagai, Y, Takeuchi, O and Akira, S (2008). TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev 60: 795-804.
15. Hama, S, Akita, H, Ito, R, Mizuguchi, H, Hayakawa, T and Harashima, H (2006). Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Mol Ther 13: 786-794.
16. Rajendran, L, Knölker, HJ and Simons, K (2010). Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 9: 29-42.
17. Zhang, J, Wong, H, Ramanan, S, Cheong, D, Leong, A and Hooi, SC (2003). The proline-rich acidic protein is epigenetically regulated and inhibits growth of cancer cell lines. Cancer Res 63: 6658-6665. (Pubitemid 37322944)
18. Deloukas, P, Earthrowl, ME, Grafham, DV, Rubenfield, M, French, L, Steward, CA et al. (2004). The DNA sequence and comparative analysis of human chromosome 10. Nature 429: 375-381. (Pubitemid 38715124)
19. Hasse, A, Schulz, WA and Sies, H (1992). De novo methylation of transfected CAT gene plasmid constructs in F9 mouse embryonal carcinoma cells. Biochim Biophys Acta 1131: 16-22.
20. Tasseron-de Jong, JG, den Dulk, H, van de Putte, P and Giphart-Gassler, M (1989). De novo methylation as major event in the inactivation of transfected herpesvirus thymidine kinase genes in human cells. Biochim Biophys Acta 1007: 215-223. (Pubitemid 19056432)
21. Bryans, M, Kass, S, Seivwright, C and Adams, RL (1992). Vector methylation inhibits transcription from the SV40 early promoter. FEBS Lett 309: 97-102.
22. Akiva, P, Toporik, A, Edelheit, S, Peretz, Y, Diber, A, Shemesh, R et al. (2006). Transcription-mediated gene fusion in the human genome. Genome Res 16: 30-36. (Pubitemid 43048931)
23. Parra, G, Reymond, A, Dabbouseh, N, Dermitzakis, ET, Castelo, R, Thomson, TM et al. (2006). Tandem chimerism as a means to increase protein complexity in the human genome. Genome Res 16: 37-44. (Pubitemid 43048932)
24. Mendes Soares, LM and Valcárcel, J (2006). The expanding transcriptome: the genome as the 'Book of Sand'. EMBO J 25: 923-931. (Pubitemid 43372107)
25. Takahara, T, Tasic, B, Maniatis, T, Akanuma, H and Yanagisawa, S (2005). Delay in synthesis of the 3' splice site promotes trans-splicing of the preceding 5' splice site. Mol Cell 18: 245-251.
26. Hashimoto, S, Suzuki, Y, Kasai, Y, Morohoshi, K, Yamada, T, Sese, J et al. (2004). 5'-end SAGE for the analysis of transcriptional start sites. Nat Biotechnol 22: 1146-1149. (Pubitemid 39166853)
27. Muttray, AF, Cox, RL, Reinisch, CL and Baldwin, SA (2007). Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues. Mar Biotechnol 9: 217-230. (Pubitemid 46675839)
28. Liu, Y and Kulesz-Martin, M (2001). p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Carcinogenesis 22: 851-860. (Pubitemid 32514948)
29. Zhao, S, Gwyn, LM, De, P and Rodgers, KK (2009). A non-sequence-specific DNA binding mode of RAG1 is inhibited by RAG2. J Mol Biol 387: 744-758.
30. Kanaya, E, Nakajima, N and Okada, K (2002). Non-sequence-specific DNA binding by the FILAMENTOUS FLOWER protein from Arabidopsis thaliana is reduced by EDTA. J Biol Chem 277: 11957-11964. (Pubitemid 34952755)
31. Bishop, CL, Ramalho, M, Nadkarni, N, May Kong, W, Higgins, CF and Krauzewicz, N (2006). Role for centromeric heterochromatin and PML nuclear bodies in the cellular response to foreign DNA. Mol Cell Biol 26: 2583-2594.
32. Hebbar, PB and Archer, TK (2008). Altered histone H1 stoichiometry and an absence of nucleosome positioning on transfected DNA. J Biol Chem 283: 4595-4601.
33. Riu, E, Chen, ZY, Xu, H, He, CY and Kay, MA (2007). Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther 15: 1348-1355. (Pubitemid 46965331)
34. Pong, RC, Roark, R, Ou, JY, Fan, J, Stanfield, J, Frenkel, E et al. (2006). Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application. Cancer Res 66: 8822-8828. (Pubitemid 44449200)
35. Kitazono, M, Rao, VK, Robey, R, Aikou, T, Bates, S, Fojo, T et al. (2002). Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood 99: 2248-2251. (Pubitemid 34525515)
36. Sasaki, Y, Negishi, H, Idogawa, M, Suzuki, H, Mita, H, Toyota, M et al. (2008). Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models. Mol Cancer Ther 7: 779-787. (Pubitemid 351551031)
37. Goldsmith, ME, Aguila, A, Steadman, K, Martinez, A, Steinberg, SM, Alley, MC et al. (2007). The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Mol Cancer Ther 6: 496-505. (Pubitemid 46332451)
38. Grassi, G, Maccaroni, P, Meyer, R, Kaiser, H, D'Ambrosio, E, Pascale, E et al. (2003). Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 24: 1625-1635. (Pubitemid 37304667)
39. Qiu, GH, Xie, H, Wheelhouse, N, Harrison, D, Chen, GG, Salto-Tellez, M et al. (2007). Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol 46: 655-663. (Pubitemid 46420382)
40. el-Deiry, WS, Tokino, T, Velculescu, VE, Levy, DB, Parsons, R, Trent, JM et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825. (Pubitemid 23346378)
41. He, TC, Sparks, AB, Rago, C, Hermeking, H, Zawel, L, da Costa, LT et al. (1998). Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512. (Pubitemid 28425575)
42. Katabami, M, Donninger, H, Hommura, F, Leaner, VD, Kinoshita, I, Chick, JF et al. (2005). Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorageindependent growth in RAT1a cells. J Biol Chem 280: 16728-16738. (Pubitemid 41389130)
43. Schuettengruber, B, Simboeck, E, Khier, H and Seiser, C (2003). Autoregulation of mouse histone deacetylase 1 expression. Mol Cell Biol 23: 6993-7004. (Pubitemid 37214666)